Cure by design

Choukri Ben Mamouncbmamoun@eliv5therapeutics.com

Department of MedicineInfectious Diseases

Yale

Develop a breakthrough therapy for radical cure of fungal infections

Safe

Radical cure

Potent

ELIV5’S MISSIONCure by design

William HungerfordYale / Chemistry

Choukri Ben MamounFounder and CEOYale

Peter Gareiss, PhDYale / Biology

Yulia Surovsteva, PhDYale / Biology

Marwan Azar, MDYale, Consultant

Jose Thekkiniath, PhDYale / Scientific Manager

ELIV5 TEAM

Cure by design

PROBLEM & OPPORTUNITY

Fungal Infections1.5 million deaths worldwide

97,000 deaths in USCandida and Aspergillus

Pulmonary Aspergillosis

HighMedium

Very High

Low

Cure by design

GLOBAL ANTIFUNGAL MARKET>$12B IN 2018 $19.3B by 2023

Major Players

Abbott LaboratoriesPfizerMerck

Arbor Pharma, IncBaxter

Astella Pharma IncBayer Healthcare

Azoles42%

Echinochandins33%

Polyenes9%

Allyamines6%

Pyrimdines4%

Others6%

www.marketresearchfuture.com; www.grandviewresearch.com

HIGH MORTALITY RATES DESPITE THERAPY

Fungal Disease Estimated Cases/year

Estimated Mortality Rates (% of infected)

Cryptococcus infections > 1,000,000 20 – 70%Candidiasis >400,000 10 - 75%Aspergillosis >200,000 30 – 95%Pneumocystis Pneumonia >400,000 20 – 80%Mucormycosis >11,000 30 - 90%

Pianalto and Asplaugh, J. Fungi 2016

Cure by design

VOL. CLXVIII . . . No. 58,289 + © 2019 The New York Times Company NEW YORK, SATURDAY, APRIL 6, 2019

Late EditionToday, clouds and fog giving way tosome sunshine, milder, high 66. To-night, partly cloudy, low 49. Tomor-row, sunshine mixing with clouds,high 65. Weather map is on Page C8.

$3.00

FUNGAL INFECTIONS KILL MORE PEOPLE THAN TB AND MALARIACure by design

Cure by designUNIQUE TARGET AND MODE OF ACTION

Pantothenate CoA

EliV5Inhibitors

PanK PPCS PPCDC PPAT DPCK

Cure by design

FIRST-IN-CLASS INHIBITORS IDENTIFIED

131,334 Compounds

(+ 25,000 ongoing)

25 Hits

50 Analogs

Actives

3 Chemotypes3 Singletons

Cure by design

TECHNOLOGY & PRODUCTS STRENGTHS

Hit

Prop

ertie

s

Highly selective

Excellent safety profile

Novel compounds (IP: competitive advantage)

CompoundEC50 (µM) LD50 (µM)

AspergillusPanK

Human PanK3 HeLa

YU182690 (Chemotype 1: PT) 0.74 >50 >50

YU253854 (Chemotype 2: NP) 8.6 >100 >100

YU196223 (Chemotype 3: SA) 3.6 >100 >100

-7 -6 -5 -4

-5 0

0

5 0

1 0 0

Y U 2 5 3 8 5 4N itr ile

lo g [ ] , MPe

rce

nt

Inh

ibit

ion

A .fu m . P a n K

h u P a n K 3 Y U 2 5 3 8 5 4

AfPanKHuPanK3

Cure by design ELIV5 1-2 PUNCH STRATEGY

Pantothenate CoA Ergosterol

• Azoles (Voriconazole)• Polyenes (Ampho-B)• Allylamines (Terbinafine)• Morpholines (Amorolfine)

EliV5Inhibitors

1-2 PUNCH STRATEGY FOR RADICAL CURE

PanK100% active

20

40

60

80

100

No drug

AmphoB(1 µg/ml)

No drug

AmphoB(1 µg/ml)

Wild type PanK mutant

% G

row

th

PanKactivity

100%

8%

100%

8%

AmphoB

-

-

+

+

Cell numbers106 105 104 103 102 10

PanKactivity

100%

8%

100%

8%

AmphoB

-

-

+

+

Cell numbers106 105 104 103 102 10

Cure by design

PanK8% active

20

40

60

80

100

No drug

AmphoB(1 µg/ml)

No drug

AmphoB(1 µg/ml)

Wild type PanK mutant

% G

row

th

PanKactivity

100%

8%

100%

8%

AmphoB

-

-

+

+

Cell numbers106 105 104 103 102 10

PanKactivity

100%

8%

100%

8%

AmphoB

-

-

+

+

Cell numbers106 105 104 103 102 10

Ampho-B (µg/ml)a

-Pan

Am

(µg/

ml)

Synergy between a-PanAm and Ampho-B

Seed $430K

Lead Identification

ASK $1.8MDrug

OptimizationIn vitroEfficacy Pharmacology

In vivoEfficacy

Cure by designUSE OF FUNDS

Clinical CandidatesPhase I

Cure by design

SUMMARY

Novel inhibitors

Novel mode of action

Novel strategy for radical cure

Competitive advantage

(IP to 2039)

ELIV5 TECHNOLOGY AND COMPETITIVE ADVANTAGE

ASK$1.8M

MilestoneIdentify clinical

candidates

GoalTherapy for radical cure

Cure by design

STRATEGIC PLANNING

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027

Pre-clinical Launch

PITCH$438,870

STTR+SBIR

Private ($1.8M) Acquisition / IPO

Strategic partner/Joint Venture

Alli

ance

s / p

artn

ersh

ips

Clinical